Tramadol--the impact of its pharmacokinetic and pharmacodynamic
properties on the clinical management of pain
by
Klotz U.
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart, Germany.
ulrich.klotz@ikp-stuttgart.de
Arzneimittelforschung. 2003;53(10):681-7

ABSTRACT

Tramadol (CAS 36282-47-0) plays an important role in the management of pain. With its dual mechanism of action (opioid agonist; weak noradrenaline and serotonin reuptake inhibitor) tramadol provides a kind of combined/adjuvant pain therapy. Besides its proven clinical efficacy tramadol is a safe drug as respiratory depression, cardiovascular side effects, drug abuse and dependence are of minor clinical relevance, unlike some other opioids. Following oral administration the bioavailability of tramadol is high (70-90%) and with new slow release preparations twice daily administration enables effective pain control. Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg). Elimination is primarily by the hepatic route (metabolism by CYP2D6 to an active metabolite and by CYP3A4 and CYP2B6) and partly by the renal route (up to 30% of dose). Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min). The interaction potential of tramadol is neglectable, as it does not affect the disposition of other drugs. It should be taken into account that inducers (e.g. carbamazepine) or inhibitors (e.g. quinidine for CY2D6) of drug metabolism might modify the elimination of tramadol. Likewise, if kidney (creatinine clearance below 30 ml/min) or hepatic function is severely impaired, some dosage reduction (approximately by 50%) or extension of the dosage interval should be considered. In conclusion, tramadol is an effective and safe analgesic with a very low interaction potential. Therefore it represents a drug of first choice if moderate to severe pain states have to be treated in pediatric, adult and elderly patients including those with poor cardiopulmonary function.

Dosage
Sources
Synthesis
Prescription
Antidepressant
The tramadol option
Tramadol: metabolites
Tramadol: mechanisms
Tramadol and analgesia
Tramadol and acute pain
Tramadol (Ultram) : structure
Tramadol as an antidepressant
Tramadol: risk/benefit analysis
Tramadol versus buprenorphine
Methadone for tramadol addicts?
Tramadol/sustained release preparation
Pharmacokinetics and pharmacodynamics
Tramadol, depression and Parkinson's disease
CYP2D6 polymorphism and tramadol (Ultram) metabolism

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family